Schering's Dermatology business to be called Intendis
"We are convinced that an autonomous dermatology business will give us a high degree of flexibility in creating strategic partnerships," said Professor Wolfgang Kehr, Head of Schering's Center of Dermatology and designated Chairman of Intendis' Management Board. "We have a number of successful products such as Finacea®, Advantan® and Psorcutan® Beta and will systematically expand our business. Our aim is to become one of the ten largest pharmaceutical companies world-wide in the field of dermatology by 2010."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.